News Center
Welcome to the News Center, please read the latest news and activities of Aktin.
2026-09-20
AkTilin™ Intermediates: The Reliable Link to Your API
AkTilin™ is AKTINPHARM®’s dedicated intermediate product line developed for pharmaceutical enterprises, biotechnology companies, and Marketing Authorization Holders (MAHs).
2026-09-20
AkProva™ APIs: Generic APIs Developed Beyond the Generic Standard
AkProva™ is the dedicated API portfolio of AKTINPHARM®, developed for generic drugs and established pharmaceutical products.
2026-09-20
AKTINPHARM® High-Potency ADC Linker-Payloads Integrated CRDMO Solutions
Leveraging three proprietary platforms—Phytopower® Development Platform of Bioactive Molecules & Ingredients from Global Medicinal Plants, Aktinsyn® Technology Platform of Synthetic Chemistry, and Aktinbio® Development Platform of Biotechnology, AKTINPHARM® provides CRDMO services for ADC linker-payloads to pharmaceutical enterprises, biotechnology companies, and Marketing Authorization Holders (MAHs).
2026-09-20
Empowering Next-Gen Nucleic Acid Therapies: AKTINPHARM® CRDMO Solutions for Nucleic Acid Delivery & Saponin Adjuvants
Leveraging our proprietary technology platforms — Phytopower® Development Platform of Bioactive Molecules & Ingredients from Global Medicinal Plants, Aktinsyn® Technology Platform of Synthetic Chemistry, and Aktinbio® Development Platform of Biotechnology, AKTINPHARM® provides professional products and CRDMO services for nucleic acid delivery systems and saponin vaccine adjuvants to global pharmaceutical enterprises, biotech companies, and Marketing Authorization Holders (MAHs).
2026-09-20
AkVEri® Life Science Reagents: Supporting Foundational Scientific Research Exploration, Empowering Pharmaceutical Industry Innovation
AkVEri® is dedicated to providing high-purity, traceable life science reagents and customized solutions to global pharmaceutical enterprises, research institutions, contract research organizations (CROs), and quality control laboratories.
